Primecap Management Co. CA Sells 10,300 Shares of Accuray Incorporated (NASDAQ:ARAY)

Primecap Management Co. CA lessened its holdings in Accuray Incorporated (NASDAQ:ARAY) by 6.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 162,300 shares of the medical equipment provider’s stock after selling 10,300 shares during the period. Primecap Management Co. CA’s holdings in Accuray were worth $321,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Caprock Group LLC bought a new position in shares of Accuray in the third quarter worth about $36,000. Intech Investment Management LLC purchased a new stake in Accuray in the 3rd quarter valued at about $41,000. Thrivent Financial for Lutherans bought a new position in Accuray in the 3rd quarter worth about $57,000. SG Americas Securities LLC increased its position in shares of Accuray by 37.4% during the fourth quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 12,259 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Accuray during the third quarter valued at approximately $231,000. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Stock Performance

Shares of Accuray stock opened at $1.87 on Thursday. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The stock’s fifty day moving average price is $2.14 and its 200-day moving average price is $2.00. The firm has a market cap of $192.29 million, a P/E ratio of -37.40 and a beta of 1.46. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $2.95.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, equities research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Accuray from a “hold” rating to a “buy” rating in a report on Saturday, March 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.